News Room

Shanghai FTZ Fund invests in GeneChem, an enterprise of translational medicine platform

2020-04-08

Recently, Shanghai FTZ Fund has invested in GeneChem, a translational medicine platform enterprise. GeneChem is an innovative diagnosis and treatment product development company with translational medicine as its core model. The company is committed to working with doctors to solve the problem of new drug research and development of unique and high incidence diseases in China, and has formed a unique translational medicine system. Wuhan Renfu and Zhangjiang Ketou also participated in the financing of the company.

SHFTZFUND won multiple awards including ‘PEAS Best Investment Institution’ in 2023.

Shanghai FTZ Fund successfully holds the "Lingang Industry Salon" for Spatial Information Industry

This activity is a brand series of activities held by Shanghai FTZ Fund and its Lingang Special Area Sci-tech Innovation Fund on a regular basis.

Shanghai FTZ Fund receives China Bridge 2023 Annual Awards

Lately, Shanghai FTZ Fund has been awarded China Bridge "2023 Top 50 Private Equity Investment Institutions in China" and "2023 Best Chinese Capital Investment Institution".

Shanghai FTZ Fund awarded ZERO2IPO 2023 "Chinese State-owned Capital Investment Institutions Top50"

Today, ZERO2IPO published "China Venture Capital & Private Equity Annual Ranking 2023", and Shanghai FTZ Fund has been awarded 2023 "Chinese State-owned Capital Investment Institutions Top50"

Shanghai FTZ Fund
Wechat Official Account